300 related articles for article (PubMed ID: 26039201)
1. The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.
Or-Geva N; Reisner Y
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S14-20. PubMed ID: 26039201
[TBL] [Abstract][Full Text] [Related]
2. Megadose stem cell administration as a route to mixed chimerism.
Or-Geva N; Reisner Y
Curr Opin Organ Transplant; 2014 Aug; 19(4):334-41. PubMed ID: 24905022
[TBL] [Abstract][Full Text] [Related]
3. Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: the role of ex-vivo generated donor CD8+ T cells with central memory phenotype.
Ophir E; Eidelstein Y; Bachar-Lustig E; Hagin D; Or-Geva N; Lask A; Reisner Y
Best Pract Res Clin Haematol; 2011 Sep; 24(3):393-401. PubMed ID: 21925092
[TBL] [Abstract][Full Text] [Related]
4. Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy.
Reisner Y; Or-Geva N
Semin Hematol; 2019 Jul; 56(3):173-182. PubMed ID: 31202427
[TBL] [Abstract][Full Text] [Related]
5. Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.
Ophir E; Or-Geva N; Gurevich I; Tal O; Eidelstein Y; Shezen E; Margalit R; Lask A; Shakhar G; Hagin D; Bachar-Lustig E; Reich-Zeliger S; Beilhack A; Negrin R; Reisner Y
Blood; 2013 Feb; 121(7):1220-8. PubMed ID: 23223359
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. The evolution of T-cell depletion in haploidentical stem-cell transplantation.
Or-Geva N; Reisner Y
Br J Haematol; 2016 Mar; 172(5):667-84. PubMed ID: 26684279
[TBL] [Abstract][Full Text] [Related]
8. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
9. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
10. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
11. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
Maris M; Storb R
Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
[TBL] [Abstract][Full Text] [Related]
12. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
[TBL] [Abstract][Full Text] [Related]
13. Toward safer haploidnetical hematopoietic stem cell transplantation.
Sidlik-Muskatel R; Reisner Y
Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):733-737. PubMed ID: 31431713
[TBL] [Abstract][Full Text] [Related]
14. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
15. Exercising 'veto' power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance.
Or-Geva N; Reisner Y
Regen Med; 2015; 10(3):239-42. PubMed ID: 25933232
[No Abstract] [Full Text] [Related]
16. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
17. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
18. Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.
Kim N; Lee H; Shin J; Nam YS; Im KI; Lim JY; Lee ES; Kang YN; Park SH; Cho SG
PLoS One; 2015; 10(5):e0126318. PubMed ID: 25961559
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
[TBL] [Abstract][Full Text] [Related]
20. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
